Craft

AIkido Pharma

Stock Price

$3.8

2023-02-22

Market Capitalization

$319.3 M

2023-02-22

Revenue

$123.1 M

FY, 2025

AIkido Pharma Summary

Company Summary

Overview
AIkido Pharma (formerly known as Spherix) is a biotechnology company engaged in the development of small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
Type
Public
Status
Active
Founded
1967
HQ
Bethesda, MD, US | view all locations
Website
https://aikidopharma.com/
Cybersecurity rating
Sectors

Key People

  • Anthony Hayes, Chief Executive Officer, President, Director

    • Darrell Dotson, VP & General Counsel

      LocationsView all

      2 locations detected

      • Bethesda, MD HQ

        United States

        Westmoreland Building, 6430 Rockledge Dr

      • New York, NY

        United States

        1 Rockefeller Plaza 11th floor

      AIkido Pharma Financials

      Summary Financials

      Revenue (Q1, 2026)
      $35.8M
      Net income (Q1, 2026)
      ($57.3M)
      Cash (Q1, 2026)
      $27.5M
      EBIT (Q1, 2026)
      ($37.6M)
      Enterprise value
      $294.5M

      Footer menu